Cho‐Ming Loi

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

Brion W. Murray, Chuangxing Guo, Joseph Piraino et al. · Proceedings of the National Academy of Sciences · 2010 · 318 citations · Full text

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus et al. · Molecular Cancer Therapeutics · 2008 · 220 citations · Full text

Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites

Deepak Dalvie, R. Scott Obach, Ping Kang et al. · Chemical Research in Toxicology · 2009 · 183 citations

Circulating Metabolites, Metabolomic Profiling, Secondary Metabolite +23

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

Yvonne S. Lin, G. Lockwood, Martin A. Graham et al. · Pharmacogenetics · 2001 · 134 citations

Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

Alan Brown, Tage Carlson, Cho‐Ming Loi et al. · Cancer Chemotherapy and Pharmacology · 2006 · 124 citations

Intravenous Administration, Pharmacological Study, Medicine +8